Latest On Pieris Pharmaceuticals, Inc (PIRS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-17 06:56 EST | News | Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites | N/A |  |
| 2023-05-10 19:27 EST | News | Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57M | N/A | |
| 2023-05-10 19:27 EST | News | Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-09 17:07 EST | News | Pieris Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-04-18 01:10 EST | News | Pieris spikes 11% on data for gastric cancer candidate | N/A | |
About Pieris Pharmaceuticals, Inc (PIRS):
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for onc read more...ology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
General
- Name Pieris Pharmaceuticals, Inc
- Symbol PIRS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 114
- Last Split Factor2:1
- Last Split Date2014-12-08
- Fiscal Year EndDecember
- IPO Date2015-04-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.pieris.com
Valuation
- Price/Sales (Trailing 12 Mt.) 3.17
- Price/Book (Most Recent Quarter) 3.38
- Enterprise Value Revenue 1.82
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.19
- Profit Margin -53%
- Operating Margin -51%
- Return on Assets -12%
- Return on Equity -73%
- Revenue 44.72 million
- Earnings Per Share -$0.77
- Revenue Per Share $0.83
- Gross Profit 46.28 million
- Quarterly Earnings Growth -80.6%
Highlights
- Market Capitalization 150.9 million
- EBITDA -42862000
- PE Ratio -1.02
- Analyst Target Price $9
- Book Value Per Share $0.78
Share Statistics
- Shares Outstanding 55.97 million
- Shares Float 43.18 million
- % Held by Insiders 9%
- % Held by Institutions 61.05%
- Shares Short 2.51 million
- Shares Short Prior Month 2.32 million
- Short Ratio 4.62
- Short % of Float 5%
- Short % of Shares Outstanding 4%
Technicals
- Beta 1.29
- 52 Week High $3.64
- 52 Week Low $1.8
- 50 Day Moving Average 2.76
- 200 Day Moving Average 2.65
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Pieris Pharmaceuticals, Inc (PIRS) Dividend Calendar:
Pieris Pharmaceuticals, Inc (PIRS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Pieris Pharmaceuticals, Inc (PIRS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | 11.82 million | 11.33 million | 12.76 million | 14.12 million | 13.21 million |
| Income Before Tax | -14.28 million | -4.95 million | -3.6 million | -771000 | -2.59 million |
| Selling General Administrative | 4.12 million | 4.57 million | 4.36 million | 4.48 million | 4.84 million |
| Gross Profit | N/A | N/A | N/A | 17.27 million | 15.13 million |
| Ebit | -12.5 million | -4.17 million | -3.32 million | -1.33 million | -2.91 million |
| Operating Income | -13 million | -4.66 million | -3.86 million | -1.33 million | -2.91 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 2.94 million | 11.25 million | 13.26 million | 17.27 million | 15.13 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | -1.34 million | -424000 | -60000 | 559000 | 322000 |
| Net Income From Continuing Operations | -14.28 million | -4.95 million | -3.6 million | -771000 | -2.59 million |
| Net Income Applicable to Common Shares | N/A | -4.95 million | N/A | -3.6 million | -2.59 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | 18.35 million | 5.6 million | 414000 | N/A | 4.36 million |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | 4.12 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 9.62 million | N/A | N/A | N/A | 221000 |
| Change to Operating Activities | N/A | N/A | N/A | N/A | -12.24 million |
| Change in Cash | 22.59 million | -3.13 million | -14.83 million | N/A | -8.83 million |
| Total Cash from Operating Activities | -7.57 million | -9.78 million | -15.13 million | N/A | -12.65 million |
| Depreciation | 495000 | 487000 | 538000 | N/A | 159000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | N/A | N/A | 2.02 million |
| Capital Expenditures | N/A | 1.06 million | 1.93 million | N/A | 232000 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 72.03 million | N/A | 73.97 million | 89.75 million | 96.11 million |
| Total Stockholder Equity | 43.69 million | N/A | 49.81 million | 51.35 million | 20.64 million |
| Other Current Liabilities | 664000 | N/A | 512000 | 11.26 million | 28.34 million |
| Total Assets | 115.72 million | N/A | 123.77 million | 141.1 million | 116.75 million |
| Common Stock | N/A | 46.67 million | N/A | 51.35 million | 49000 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -197.01 million | N/A | -177.77 million | N/A | -173.41 million |
| Other Liabilities | N/A | 37.85 million | N/A | 47.26 million | 56.26 million |
| Other Assets | N/A | 1.98 million | N/A | 3.15 million | 7.77 million |
| Cash | 66.89 million | N/A | 47.43 million | 62.26 million | 46.07 million |
| Total Current Liabilities | 19.69 million | N/A | 20.48 million | 27 million | 39.85 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | -697000 |
| Property, Plant & Equipment | N/A | 23.78 million | N/A | 22.94 million | 11.01 million |
| Total Current Assets | 88.66 million | N/A | 98.37 million | 115.01 million | 97.97 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | N/A | 46.67 million | N/A | 51.35 million | 20.64 million |
| Short Term Investments | 15.75 million | N/A | 39.33 million | 41.89 million | 40.18 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.15 million | N/A | 3.5 million | 5.8 million | 5.44 million |
Pieris Pharmaceuticals, Inc (PIRS) Chart:
Pieris Pharmaceuticals, Inc (PIRS) News:
Below you will find a list of latest news for Pieris Pharmaceuticals, Inc (PIRS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Pieris Pharmaceuticals, Inc (PIRS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest PIRS Trades:
Pieris Pharmaceuticals, Inc (PIRS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 8-K (Current report) | |
| 2020-11-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-09-09 | 8-K (Current report) | |
| 2020-08-10 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-07 | CT ORDER (Confidential treatment order) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-20 | 8-K (Current report) | |
| 2020-06-30 | 8-K (Current report) | |
| 2020-06-30 | 8-K (Current report) | |
| 2020-06-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-25 | 4 (Statement of changes in beneficial ownership of securities) | |
Pieris Pharmaceuticals, Inc (PIRS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Pieris Pharmaceuticals, Inc (PIRS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 9%
Institutional Ownership: 6105%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-07-21 | Aquilo Capital Management, LLC | 10% Share Holder | Sell | 1,900,000.00 | 2.95 | 5,605,000.00 | 3,675,530.00 | |
| 2019-09-06 | PARTNERS L P/IL BVF | 10% Share Holder | Sell | 25,720.00 | 4.50 | 115,724.57 | 2,233,074.00 | |
| 2019-09-06 | PARTNERS L P/IL BVF | 10% Share Holder | Sell | 23,152.00 | 4.50 | 104,170.11 | 2,385,055.00 | |
| 2019-09-06 | PARTNERS L P/IL BVF | 10% Share Holder | Sell | 1,128.00 | 4.50 | 5,075.32 | 314,139.00 | |
| 2018-09-14 | CHRISTOPHER P KIRITSY | Director | Buy | 5,000.00 | 5.11 | 25,525.00 | 10,000.00 | |